RxDoctor Payments Data

Rodolfo Freire, MD

Internal Medicine · Naples, FLNPI 1861638280

Payments from drug & device makers

$2,109in general payments, 2019–2025

Across 108 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$447
  • Amgen$430
  • AstraZeneca$231
  • Novo Nordisk$225
  • Sanofi-aventis U.S. LLC$170
  • Corcept Therapeutics$99
  • plus $507 from 13 others

What the payments were for

  • Food & beverage$2,109100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,109 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$248,118
Medicare patients
175
Services billed
3,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$113,172
EliquisApixaban78$86,619
TradjentaLinagliptin60$75,670
JardianceEmpagliflozin43$62,961
XareltoRivaroxaban28$40,903
FarxigaDapagliflozin Propanediol24$29,729
Repatha SyringeEvolocumab28$21,626
ProliaDenosumab12$21,514
Trijardy XrEmpaglifloz/Linaglip/Metformin18$18,394
Soliqua 100-33Insulin Glargine/Lixisenatide16$17,997
MyrbetriqMirabegron14$14,585
SymbicortBudesonide/Formoterol Fumarate36$14,242
GlyxambiEmpagliflozin/Linagliptin12$13,252
VascepaIcosapent Ethyl16$8,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog50$5,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Trijardy Xr, Glyxambi$447$170,277133 claims
Novo NordiskOzempic$225$113,17272 claims
AstraZenecaFarxiga, Symbicort$231$43,97160 claims
Johnson & JohnsonXarelto$18$40,90328 claims
AmgenProlia$430$21,51412 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$170$17,99716 claims
Astellas Pharma US IncMyrbetriq$90$14,58514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →